Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Short Interest Down 86.7% in February

Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 9,700 shares, a decline of 86.7% from the February 13th total of 73,200 shares. Based on an average daily volume of 132,300 shares, the short-interest ratio is presently 0.1 days.

Tevogen Bio Trading Up 0.8 %

TVGNW opened at $0.06 on Thursday. The business’s 50-day simple moving average is $0.07 and its 200-day simple moving average is $0.05. Tevogen Bio has a one year low of $0.01 and a one year high of $0.15.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.